Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/red-cell-storage-lesion-and-additive-solutions-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Transfusion MedicineRed Cell Storage Lesion and Additive Solutions: A Patent Landscape
- One assignee dominates the ranking. the leader holds 137 of the records tracked, against a fifth-place assignee at just 1 — a steep drop rather than a gradual tail.
- Filing has cooled from its 2018 peak. the field peaked at 47 records in 2018, and confirmed filings fell from 16 in 2021 to 5 in 2024, a -69% move over that span.
- Claim activity concentrates in two IPC classes. A61K (medicinal preparations) and A61P (therapeutic activity) each cover the large majority of the 173 records in scope, leaving device- and container-side classes comparatively thin.
173
Published Records
-69%
Filing Growth 2021→2024
IL
Leading Jurisdiction
9
Active Filers Ranked
Filing growth compares 2021 (16 records) with 2024 (5) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Red cell storage lesion refers to the biochemical and structural changes that stored red blood cells undergo before transfusion — falling ATP levels, rising hemolysis rate, and microvesicle formation that together limit shelf life and post-transfusion recovery. Patent activity in this space centres on additive solution composition, storage duration extension and the containers and devices used to hold blood products ex vivo. This landscape draws on 173 published patent families filed between 2015 and mid-2026.
The dataset spans preparation chemistry, therapeutic-activity claims tied to transfused blood, and the fluid-handling devices and containers that interact with stored cells. Coverage runs through 2026-07-31; because publication lags filing by roughly 18 months, the most recent one to two years in any trend understate actual filing activity.
Filing activity, 2017–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trends and technology composition
Two views of the same 173 records: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
From a 2018 peak to a cooling trend
Filings ran from 27 in 2017 to a peak of 47 in 2018, then eased. Using the last fully comparable window, confirmed filings dropped from 16 in 2021 to 5 in 2024, a -69% change. 2025 and 2026 figures are still filling in and should not be read as a continued decline.
Preparation and therapeutic-activity classes dominate
A61K (medicinal preparations) appears in 86.7% of the 173 records and A61P (therapeutic activity) in 73.4%, reflecting the additive-solution and clinical-effect focus of most filings. A61M (devices for body fluids) reaches 40.5%, while container claims under A61J sit at 8.7% and polymer-additive claims under C08K at just 2.3% — both comparatively open.
Shares are the percentage of the 173 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Red Cell Storage Lesion and Additive Solutions with Eureka
This page is one run against one query. Ask Eureka your own question about red cell storage lesion and additive solutions and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited priority filings
Representative recent filing
Compositions, kits, and methods for the preservation of blood products (WO2025212681A1)
OHIO STATE INNOVATION FOUNDATION
Provided herein are compositions and methods for reducing the concentration of hemolytic biproducts in a blood product stored ex vivo. These compositions and methods can also be used to prolong the shelf life of blood products ex vivo. Also provided herein are sterile blood bags that contain the compositions described herein.Filed by Ohio State Innovation Foundation, published 2025-10-09 — one of the most recent entries in the dataset and a marker of continued activity from an academic-affiliated assignee.
Highest-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2016187353A1 | Methods for the storage of whole blood, and compositions thereof | 34 |
| 2 | WO2017223377A1 | Methods for managing adverse events in patient populations requiring transfusion | 22 |
| 3 | US20120294826A1 | Methods, kits and compositions for ameliorating adverse effects associated with transfusion of aged red blood… | 18 |
| 4 | US20180133255A1 | Methods for the Storage of Whole Blood, and Compositions Thereof | 15 |
| 5 | WO2015124236A1 | Medical containers and system components with non-DEHP plasticizers for storing red blood cell products, plas… | 12 |
| 6 | US20190388467A1 | Methods for managing adverse events in patient populations requiring transfusion | 7 |
| 7 | WO2021231650A2 | DEHP-free blood storage and methods of use thereof | 5 |
| 8 | US20200276234A1 | Methods for managing adverse events in patient populations requiring transfusion | 5 |
| 9 | US20200197438A1 | Methods and treatment of trauma | 5 |
| 10 | US11090331B2 | Methods and treatment for reducing the risk of an inflammatory response | 4 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus — treat them as a signal of influence on the field, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Three patterns worth acting on before drafting claims or scoping freedom-to-operate in this space.
Concentration
137 vs. 1
leader vs. fifth-ranked assignee
One assignee holds most of the ranked filings
The ranking returns nine companies total, and the leader accounts for 137 of the records in it while the fifth-place assignee holds just 1. That is a steep drop, not a gradual tail — new entrants are filing individually rather than building portfolios of scale.
Assignee ranking, 9 companies
Momentum
-69%
2021 to 2024 filings
Confirmed filing volume has eased from its peak
After peaking at 47 records in 2018, filings fell from 16 in 2021 to 5 in 2024. Because 2025-2026 data is still incomplete due to publication lag, this should be read as a cooling from peak activity rather than a signal that the field is closed.
Filing trend, 2017-2026
Technology mix
40.5%
of 173 records carry A61M device claims
Device and container claims trail composition claims
A61K and A61P claims cover the substantial majority of records, but A61M device claims sit at 40.5% and A61J container claims at only 8.7% of the 173 records in scope. Fluid-handling and container-side innovation is comparatively under-claimed relative to solution chemistry.
IPC composition, 173 records
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to red cell storage lesion and additive solutions, with the prior art for and against each one.
Co-assignee activity is limited
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Hemanext Inc. | New Health Sciences, Inc. | 6 |
| SPITALNIK STEVEN L | HOD ELDAD A | 1 |
| SPITALNIK STEVEN L | BRITTENHAM GARY M | 1 |
| HOD ELDAD A | BRITTENHAM GARY M | 1 |
Only 4 co-assignee pairs appear in the dataset, the strongest linking two of the leading assignees on 6 shared records — most other filings, including the academic and named-inventor assignees, proceed without a named co-assignee.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where activity has cooled
The ranked field is small and top-heavy, with momentum data suggesting most named assignees have gone quiet in the latest tracked year.
Leader
137 records
of the ranked total
A single assignee dominates the ranking
One company accounts for the large majority of the ranked filings, with the strongest co-assignee link in the dataset (6 shared records) running to a second, closely associated assignee — suggesting related corporate entities rather than independent competitors.
Assignee ranking, 9 companies
Momentum
-75% YoY
leader's latest-year change
Even the leader has slowed
The leading assignee logged just 1 filing in the latest tracked year, down 75% year over year. A university-affiliated foundation also logged 1 filing in the latest year, while several other named assignees, including a state innovation foundation, show zero filings and a -100% YoY change.
Recent-year momentum by assignee
Long tail
1 record
fifth-place assignee
Individual inventors and foundations round out the field
Named-inventor assignees and university-affiliated foundations appear alongside the corporate leaders, each holding small numbers of records. This mix points to academic research feeding into a field otherwise controlled by one commercial group.
Assignee ranking, 9 companies
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Hemanext Inc. | 1 | -75% |
| University of Florida Research Foundation, Inc. | 1 | — |
| New Health Sciences, Inc. | 0 | — |
| FRESENIUS HEMOCARE NETHERLANDS | 0 | — |
| Fresenius Kabi Deutschland GmbH | 0 | — |
| Ohio State Innovation Foundation | 0 | -100% |
| SPITALNIK STEVEN L | 0 | — |
| HOD ELDAD A | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The published landscape is a starting point; the questions below go further than a static report can.
Test freedom-to-operate against the leader's portfolio
With one assignee holding 137 of the ranked records, a candidate composition or device claim needs to be checked against that portfolio specifically, not just the field average.
Run an FTO check in EurekaTrack the under-claimed branches as they develop
Container, device and polymer-additive classes carry far fewer records than the core additive-chemistry claims — worth monitoring for new entrants before filing there.
Set up monitoring in EurekaWatch the most-cited priority filings for family expansion
The highest-cited records in this set, several from the 2015-2017 window, remain reference points for examiners; new continuations or divisionals from those families are worth flagging early.
Explore citation trees in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on this landscape
The assignee ranking for this dataset returns nine companies, and one assignee holds 137 of the ranked records, far ahead of the rest. The fifth-ranked assignee holds only 1 record, so the field is best described as one dominant filer with a short, thin tail of academic foundations and named inventors rather than a broad competitive set. Anyone assessing competitive risk in this space should treat that leader's portfolio as the primary reference point.
Filings peaked at 47 records in 2018 and have since eased; using the last fully comparable years, confirmed filings fell from 16 in 2021 to 5 in 2024, a -69% change. Data for 2025 and 2026 is still incomplete because publication typically lags filing by around 18 months, so those later years should not yet be read as continued decline. The honest read is a cooling from a 2018 peak rather than a field that has stopped.
The large majority of the 173 records in scope carry A61K claims (medicinal preparations, 86.7%) and A61P claims (therapeutic activity, 73.4%), reflecting a focus on additive solution chemistry and its physiological effects. A61M device claims appear in 40.5% of records, while container claims under A61J and polymer-additive claims under C08K are comparatively rare, at 8.7% and 2.3% respectively. Because a single record can carry multiple IPC classes, these shares add up to more than 100%.
WO2025212681A1, filed by Ohio State Innovation Foundation and published 2025-10-09, covers compositions and methods for reducing hemolytic biproducts in ex vivo-stored blood products, methods for extending their shelf life, and sterile blood bags containing those compositions. It is one of the most recent filings in this dataset and signals continued activity from an academic-affiliated assignee even as overall filing volume has eased. Anyone drafting a similar hemolysis-reduction composition or storage-bag claim should review its specific claim scope directly rather than relying on the abstract alone.
Relative to the dense additive-chemistry claim space under A61K and A61P, device and container classes are comparatively open: A61J container claims sit at 8.7% of the 173 records and C08K polymer-additive claims at just 2.3%. Sub-areas such as DEHP-free plasticizers, microvesicle-targeted preservation methods and patient-transport storage devices show thinner filing density than the core composition claims. These are not guarantees of patentability, but they are areas where the incumbent leader's portfolio is less likely to block a well-drafted claim.
Answers are grounded in the same dataset. Derived from a Patsnap search on Red Cell Storage Lesion and Additive Solutions covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Red Cell Storage Lesion and Additive Solutions in depth with Eureka
Go past this page: query the whole red cell storage lesion and additive solutions corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.